PVI
ALNY icon

Pura Vida Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pura Vida Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,000
Closed -$7.13M – 79
2022
Q4 		$7.13M Buy
+30,000
New +$6.4M 0.37% 69
2022
Q3 		– Sell
-50,000
Closed -$7.29M – 204
2022
Q2 		$7.29M Hold
50,000
– – 0.42% 62
2022
Q1 		$8.16M Buy
+50,000
New +$7.62M 0.26% 92

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pura Vida Investments's ALNY Position: Q3 2022 in Review

Pura Vida Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 95,240 shares — an estimated $13.9M sold.

Pura Vida Investments first reported a position in ALNY in Q3 2016 and held it in 2 quarters. The position peaked at $13.9M in Q2 2022. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Pura Vida Investments reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Pura Vida Investments sold 95,240 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $13.9M.
  • Pura Vida Investments first reported a position in Alnylam Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Pura Vida Investments's Alnylam Pharmaceuticals position peaked at $13.9M in Q2 2022.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Pura Vida Investments's 13F filing for Q3 2022, filed 14 Nov 2022.